[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@EngBigData Data Monster

Data Monster posts on X about $nvo, nvo, $hims, $zeta the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

• X Week XXXXX +1,121%
• X Month XXXXX +146%
• X Months XXXXXX -XX%
• X Year XXXXXX -XX%

Mentions: XX #

• X Months XXX -XX%
• X Year XXX +17%

Followers: XXXXX #

• X Week XXXXX -XXXX%
• X Month XXXXX +0.20%
• X Months XXXXX +0.53%
• X Year XXXXX +0.36%

CreatorRank: XXXXXXX #

Social Influence

Social category influence stocks finance cryptocurrencies currencies

Social topic influence $nvo #38, nvo #35, $hims, $zeta #44, $oscr #30, $lly #69, alltime, federal reserve, ai, fed

Top accounts mentioned or mentioned by @houston20jon @bourboncap @ogtigress @chasemactrades @realdonaldtrump @kholov23 @unusualwhales @jakewujastyk @growthrapidly @holysmokas @superrobotgx @luceontsla @superrobototc @hulkinvestments @mrzackmorris @ashton1nvests @ladebackk @traderjon01 @arcstockstrader @barstoolsports

Top assets mentioned Novo-Nordisk (NVO) Hims & Hers Health, Inc. (HIMS) ZetaChain (ZETA) Oscar Health, Inc. (OSCR) Eli Lilly and Company (LLY) United Parcel Service, Inc. (UPS) UnitedHealth Group (UNH) SPDR S&P XXX ETF Trust (SPY)

Top Social Posts

Top posts by engagements in the last XX hours

"@TheRayMyers Love the lists but definitely curious on how $HIMS is overvalued"
X Link 2025-12-04T23:07Z 2473 followers, XXX engagements

"@TheRonnieVShow $ZETA gonna be wild"
X Link 2025-12-06T22:51Z 2476 followers, XXX engagements

"@StockChaser_ $NVO"
X Link 2025-12-11T19:45Z 2477 followers, XXX engagements

"@TheLongInvest Say no more. $NVO"
X Link 2025-12-11T20:00Z 2477 followers, 1485 engagements

"Dow Jones Industrial Average hitting a fresh all-time high amid broad relief from the Federal Reserve's latest policy moves while tech-heavy indices pulled back due to concerns over AI valuations sparked by Oracle's earnings report. The Fed cut its benchmark interest rate by XX basis points to a range of 3.50%-3.75% signaling potential for further easing in 2026 but hinting at a possible pause if inflation persists. 🟢 Dow Jones Industrial Average (DJI): +1.36% to 48709.12 Led gains with strong showings from blue-chip financials like JPMorgan (+2.1%) and Goldman Sachs (+1.8%). 🟢 S&P 500:"
X Link 2025-12-11T22:07Z 2477 followers, XX engagements

"$IGEX 9x the volume for 116679260 for today What did I miss"
X Link 2025-12-12T18:32Z 2477 followers, XXX engagements

"$OSCR launch mode cometh"
X Link 2025-12-12T18:33Z 2477 followers, XXX engagements

"$JD patience is key here and it's testing mine. Looking for a double bottom bounce around $XXXXX with a bounce to the downward trendline"
X Link 2025-12-12T18:49Z 2477 followers, XXX engagements

"$UPS looking for a test of the XXX EMA (Daily) to make a move higher in the $XXX range"
X Link 2025-12-12T18:53Z 2477 followers, XX engagements

"Novo Nordisk $NVO and Eli Lilly $LLY are leading pharmaceutical companies dominating the GLP-1 market for diabetes and obesity treatments. NVO's key products include Ozempic and Wegovy (semaglutide) while LLY's are Mounjaro and Zepbound (tirzepatide). In 2025 NVO has faced headwinds like clinical setbacks (e.g. CagriSema trial results and Alzheimer's failure) pricing pressures from compounded drugs and U.S. tariffs leading to a 45-50% YTD stock decline to $48-50 per share. LLY with a more diversified pipeline (including oncology and analgesics) has outperformed with XX% YTD gains to $XXX per"
X Link 2025-12-12T19:20Z 2477 followers, XXX engagements

"Business and Growth Comparison Revenue Drivers: $NVO derives XX% of sales from diabetes/obesity (H1 2025: $21.1B +24% YoY) making it vulnerable to GLP-1 competition and patent cliffs (semaglutide expires 2031 in U.S.). $LLY cardiometabolic segment is XX% of revenue but diversified into oncology (Verzenio) and immunology reducing risk. LLY's tirzepatide showed better weight-loss results in trials capturing U.S. market share (GLP-1 prescriptions: tirzepatide semaglutide in mid-2025). Pipeline and Innovation: LLY leads with next-gen GLP-1 (oral retatrutide in Phase 3) and Alzheimer's (donanemab"
X Link 2025-12-12T19:20Z 2477 followers, XXX engagements

"Investment Considerations $NVO A "safe haven" at current levelstrading at 5-year lows with a 13x P/E and 2%+ yieldoffering defensive growth (18% TTM revenue) and cash flow for buybacks/dividends (DKK 53B returned YTD). Ideal for value investors betting on rebound (analysts see 50%+ upside by 2026 via oral GLP-1 and MASH approvals). Risks: Further share loss to LLY (NVO's U.S. obesity market share down to 50%). $LLY Growth powerhouse with 30%+ revenue trajectory and diversified bets but expensive (62x P/E) and volatile (7.5% vs. NVO's 10.8%). Suited for aggressive investors; Zacks Rank #3"
X Link 2025-12-12T19:20Z 2477 followers, XXX engagements

"@Dividend_Dollar XX% $HIMS XX% $ZETA XX% $OSCR XX% $NVO XX% $UNH"
X Link 2025-12-12T20:27Z 2477 followers, XXX engagements

"President Trump says interest rates should be X% or lower next year. #Bullish #bullishmomentum #Investing $SPY"
X Link 2025-12-12T20:54Z 2477 followers, XX engagements